Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

Basit Öğe Kaydı
dc.contributor.authorGoss, G. D.
dc.contributor.authorCobo, M.
dc.contributor.authorLu, S.
dc.contributor.authorSyrigos, K.
dc.contributor.authorLee, K. H.
dc.contributor.authorGoker, E.
dc.contributor.authorGeorgoulias, V.
dc.contributor.authorLi, W.
dc.contributor.authorIsla, D.
dc.contributor.authorMorabito, A.
dc.contributor.authorMin, Y. J.
dc.contributor.authorArdizzoni, A.
dc.contributor.authorCseh, A.
dc.contributor.authorBender, S.
dc.contributor.authorFelip, E.
dc.date.accessioned2019-10-27T10:01:22Z
dc.date.available2019-10-27T10:01:22Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description43rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANYen_US
dc.description.sponsorshipEuropean Soc Med Oncol, Japanese Soc Med Oncolen_US
dc.description.sponsorshipBoehringer IngelheimBoehringer Ingelheimen_US
dc.description.sponsorshipBoehringer Ingelheim.en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://hdl.handle.net/11454/29837
dc.identifier.volume29en_US
dc.identifier.wosWOS:000459277303212en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAfatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trialen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu